Гленцет (levocetirizine) is applied in addressing symptoms related to heightened physiological activity caused by allergic responses. Its therapeutic role involves easing discomfort across two main therapeutic domains: allergic rhinitis (covering both seasonal hay fever and persistent perennial forms) and chronic idiopathic urticaria (hives).

This medication is applied across conditions involving episodic or fluctuating manifestations, and it plays a role in managing symptom clusters that may become intense or disruptive. For respiratory allergies, it is used for managing frequent sneezing, persistent runny nose, nasal congestion, and itchy, watery eyes. For skin allergies, it supports the overall symptom load by addressing symptoms related to heightened physiological activity (pruritus) and **assisting with the management of associated wheals.

“It supports the patient during difficult episodes by easing distress.”

This assists with maintaining functional stability and contributes to improved comfort when symptoms are more noticeable.

---

Quick Fact: Supports management of Persistent Itching and Nasal Congestion

Regulatory References

1. official FDA Drug Label overview on DailyMed

Eligibility for Гленцет (Levocetirizine)

Official regulatory information defines specific populations that are eligible, restricted, or prohibited from using this medicine.

Population Status	Eligibility Rule
Contraindicated	Patients with known hypersensitivity to levocetirizine, cetirizine, or any components of the formulation.
Contraindicated	Patients with end-stage renal disease (creatinine clearance less than 10 mL/min) or those undergoing hemodialysis.
Contraindicated	Pediatric patients (6 months to 11 years of age) with any degree of renal impairment.
Not Recommended	Infants younger than 6 months of age, as safety and efficacy have not been established.
Use with Caution	Patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia, spinal cord lesion).
Use with Caution	Patients with epilepsy or those at risk of convulsions.
Age-Related Rule	Tablets are approved for children 6 years of age and older. The oral solution is approved for infants 6 months of age and older.

Use in pregnancy and lactation requires medical guidance as the drug can be excreted in breast milk and should only be used if clearly needed and recommended by a physician.

Interactions with other medicines and products

Official regulatory documents detail specific interactions that may affect the drug's activity or increase the risk of combined effects.

---

Clinically Significant Interaction Categories

Category	Interaction Type & Consequence
Central Nervous System (CNS) Depressants	Pharmacodynamic: Risk of additive CNS impairment (additional reduction in alertness and central nervous system performance).
Alcohol	Pharmacodynamic: Risk of additive CNS impairment, concurrent use should be avoided.
Ritonavir	Pharmacokinetic: Increased plasma exposure (AUC) of levocetirizine by approximately 42% due to decreased clearance.
Theophylline	Pharmacokinetic: Decreased clearance of levocetirizine by 16%.
Skin Allergy Tests	Interference: Requires discontinuation of the product 72 hours before testing to prevent false negative results.

---

Other Interactions

Specific pharmacokinetic studies showed no clinically significant interaction when levocetirizine was co-administered with Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, or Pseudoephedrine.

Profile Structure

The interaction profile is formally structured to address the highest clinical concerns: first, the avoidance of additive CNS effects through pharmacodynamic interaction; and second, the pharmacokinetic alterations caused by select agents, which require consideration of the resulting higher drug exposure.

Selective H1 Receptor Inverse Agonism

The core mechanism involves Levocetirizine's high-affinity binding to and inverse agonism at the peripheral Histamine H1 Receptors ( H1 R). This action not only competitively blocks the binding of the natural mediator, histamine, but also actively suppresses the receptor's intrinsic signaling, which blocks the molecular cascade initiated by histamine. This targeted intervention modulates the subsequent physiological processes driven by histamine release.

---

Modulation of Vascular Permeability and Eosinophil Activity

By suppressing the H1 R activity on endothelial cells, the mechanism stabilizes the blood vessel walls, preventing the increased vascular permeability that leads to fluid leakage and localized tissue swelling (edema). Furthermore, the mechanism extends to secondary anti-inflammatory cell modulation, by inhibiting the movement (chemotaxis) of certain inflammatory leukocytes, such as eosinophils, to sites of heightened activity, thus supporting the maintenance of baseline activity within targeted pathways.

---

Peripheral Pathway Selectivity

The mechanism is designed for peripheral selectivity, meaning the activity is concentrated outside the central nervous system (CNS). Due to its chemical structure and active transport out of the brain by efflux pumps, the drug minimizes CNS H1 R occupancy. This focused action concentrates the suppression of histamine-mediated effects in peripheral tissues, which minimizes CNS H1 R occupancy.

How Гленцет (Levocetirizine) is Used in Practice

Гленцет, which contains levocetirizine dihydrochloride, is utilized exclusively via the oral route of administration. It is available as a 5 mg film-coated tablet and an oral solution (0.5 mg/mL), allowing for flexibility in patient populations. The administration protocol is characterized by once-daily dosing, typically recommended for intake in the evening. The medication can be taken with or without food.

Standard Dosage and Use Patterns

The standard regimen for adults and adolescents (12 years and older) is 5 mg once daily. For children aged 6 to 11 years, the dosage is 2.5 mg once daily, and this dose must not be exceeded.

The usage pattern over time is determined by the clinical scenario. For allergic symptoms that are intermittent (short-term or on-demand use), treatment may be stopped when symptoms disappear and restarted if they recur. For persistent symptoms, continuous administration throughout the exposure period, with clinical experience up to six months, is established.

Population-Specific Use

Usage requires dose adjustments based on renal function due to the medicine's primary excretion route. Patients with mild renal impairment typically reduce the dose to 2.5 mg once daily. Those with moderate impairment take 2.5 mg every other day. No dose modification is required for patients with isolated hepatic impairment. If a dose is missed, the next dose should be taken at the regularly scheduled time, without taking a double dose to compensate.

Research evidence / Overview of studies for Гленцет

Evidence for Allergic Rhinitis (Seasonal and Perennial)

The evidence base includes numerous short-term Randomized Controlled Trials (RCTs), many of which were evaluated in research contexts involving fluctuating or unstable symptoms, such as the sneezing, runny nose, and itching associated with hay fever and year-round allergies. Researchers also examined the medication in comparative studies against placebo and other specified treatments. The primary outcomes studied included changes in symptom intensity or variability using standardized severity scales, as well as outcomes reflecting daily functioning or activity level, using patient-reported questionnaires like the Quality of Life index.

Evidence for Chronic Idiopathic Urticaria (Hives)

For conditions characterized by fluctuating or episodic manifestations of skin allergies like chronic idiopathic urticaria (hives), Гленцет was studied for its impact on skin symptoms. The evidence base includes multiple short-term, placebo-controlled RCTs. Researchers examined changes in the outcomes related to physical discomfort, specifically focusing on the severity of pruritus (itching) and the size and frequency of wheals (the raised welts).

Long-Term Studies and Follow-Up

The core regulatory evidence was evaluated in research exploring short-term symptom changes over periods lasting from a few weeks up to a few months. Beyond this duration, long-term effects are not fully established by the same rigorous randomized, placebo-controlled trial design. The durability of any observed response, or the patterns of extended use, is often tracked through post-marketing surveillance and observational settings evaluating daily-life functioning, rather than through dedicated multi-year trials.

Key Research Gaps and Uncertainties

One key limitation is that follow-up durations were limited in the pivotal efficacy trials; this means that long-term effects are not fully established. Data for certain groups remain insufficient for high-certainty conclusions, particularly in specific populations, such as the very elderly or those with significant co-existing medical conditions. Research provides context but not individual predictions; the study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Levocetirizine Dihydrochloride Tablet Label Information: Clinical Pharmacology, Clinical Studies, and Adverse Reactions (DailyMed)
2. Systematic Review and Meta-analysis of Levocetirizine Efficacy and Safety in Allergic Rhinitis
3. Review of the Efficacy of Levocetirizine in the Treatment of Children and Adolescents with Allergic Rhinitis

Common questions about Гленцет (FAQ)

Q: How quickly should I expect Гленцет to start working?

Studies show that levocetirizine inhibits the wheal and flare reaction, which is a way of measuring antihistamine activity. While regulatory documents do not provide a specific 'time-to-relief' for general allergy symptoms, the medication is designed for once-daily dosing. Clinical effects have been described as persisting for at least 24 hours in certain studies.

---

Q: Does Гленцет cause weight gain or weight loss?

Official adverse reaction data indicates that weight gain has been reported during clinical trials or post-marketing surveillance. Weight change is not listed among the most common adverse reactions, which are typically those reported in 2% or more of adult users.

---

Q: Is Гленцет safe to take with common pain relievers like ibuprofen?

Official studies specifically examining drug interactions show no clinically significant issues when Гленцет is taken with certain other drugs, such as Cimetidine or Ketoconazole. Specific interaction data regarding non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are not explicitly listed in the main warnings, and official labeling does not provide a general contraindication for concurrent use.

---

Q: Is Гленцет a non-addictive medication?

Official sources confirm that levocetirizine, the active ingredient in Гленцет, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major government bodies. This means the drug has not been designated as having a high potential for misuse or addiction.

---

Q: What is the purpose of the inactive ingredients listed in Гленцет?

The inactive ingredients, also called excipients, are necessary components of the tablet or oral solution formulation. According to official documents, these substances (such as binders, fillers, and coatings) are included to help ensure the drug's stability, shelf life, and proper absorption by the body.

---

Q: Do I need a prescription to get Гленцет?

The regulatory status of levocetirizine varies by country and by formulation. In some regions, it is available as a prescription-only (Rx) medicine, while in others, it is sold as an over-the-counter (OTC) product, depending on the dosage and regulatory guidelines in that location.

---

Q: Is there a generic version of Гленцет available?

Yes, a lower-cost generic version of the active ingredient, levocetirizine, is available. The medication's patent exclusivity has ended, allowing generic manufacturers to produce and market the drug under its chemical name.

---

Q: What happens if I stop taking Гленцет suddenly?

Official product safety warnings have reported a risk of new onset pruritus (severe itching) that can occur within a few days after stopping the drug. This has been noted particularly after long-term administration. These symptoms have been noted to improve upon resuming the medication or through gradual reduction, based on reported observations.

---

Q: Does Гленцет interact with vitamins or herbal supplements?

Regulatory documents do not list specific vitamins or most common herbal supplements as having known interactions. However, official safety warnings advise general caution when combining Гленцет with any product that may cause or increase Central Nervous System (CNS) depression, which includes some sedating herbal remedies.

---

Q: Are there any specific lifestyle changes mentioned in relation to taking Гленцет?

Official warnings advise patients to avoid concurrent use of alcohol while taking this medication. Official warnings suggest avoiding engagement in hazardous activities that require complete mental alertness, such as driving or operating heavy machinery, until they know how the medicine affects them.

---

Q: Is there a list of serious side effects that require immediate medical attention?

Official regulatory documents describe severe adverse reactions that have been reported, including anaphylaxis (a severe allergic reaction) and convulsions. Any signs of a severe allergic reaction, such as swelling of the face, tongue, or throat, are officially noted as warranting immediate medical attention.

---

Q: What percentage of people experience the most common side effects of Гленцет?

In clinical trials, official product information reported that the most common adverse reactions occurred at a rate of 2% or more and greater than placebo. These common effects included somnolence (up to 6%), nasopharyngitis (up to 6%), fatigue (up to 4%), and dry mouth (up to 3%).

---

Q: Does Гленцет contain any substances that are commonly misused?

Official regulatory bodies do not classify levocetirizine as a controlled substance. This means the U.S. Drug Enforcement Administration (DEA) and other major government agencies have not designated the active ingredient in Гленцет as having a high potential for misuse.

How to Store and Dispose of Glencet (Гленцет)

The official storage and disposal requirements for Glencet (levocetirizine) are strictly defined to maintain the drug's stability and ensure safety.

Storage Domain	Official Requirement
Temperature & Environment	Store at room temperature. Protect from excessive heat and moisture.
Safety & Access	Keep out of the reach of children and pets.
Handling	Take the tablet whole; unauthorized alteration like cutting or breaking is prohibited.

These requirements mandate that the medicine must be stored at room temperature and kept away from any sources of excessive heat or moisture. The safety constraint is established by the explicit rule to ensure the product remains out of the reach of children and pets at all times. All statements reflect information documented in official governmental regulatory sources.